Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pBK-YE1-BE3 Citations (3)

Originally described in: Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions.
Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR Nat Biotechnol. 2017 Feb 13. doi: 10.1038/nbt.3803.
PubMed Journal

Articles Citing pBK-YE1-BE3

Articles
Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos. Zeng Y, Li J, Li G, Huang S, Yu W, Zhang Y, Chen D, Chen J, Liu J, Huang X. Mol Ther. 2018 Nov 7;26(11):2631-2637. doi: 10.1016/j.ymthe.2018.08.007. Epub 2018 Aug 14. PubMed
Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, Fingerhut R, Haberle J, Matos J, Robinson MD, Thony B, Schwank G. Nat Med. 2018 Oct;24(10):1519-1525. doi: 10.1038/s41591-018-0209-1. Epub 2018 Oct 8. PubMed

Associated Plasmids

Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro. Guyon A, Rousseau J, Begin FG, Bertin T, Lamothe G, Tremblay JP. Mol Ther Nucleic Acids. 2021 Mar 1;24:253-263. doi: 10.1016/j.omtn.2021.02.032. eCollection 2021 Jun 4. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.